Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.52 |
| ▸ | VCP | P55072 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | MMP14 | P50281 | 1/20 | 0.51 |
| ▸ | MMP15 | P51511 | 1/20 | 0.51 |
| ▸ | MMP16 | P51512 | 1/20 | 0.51 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7732264 | 0.94 | MAPT (0.70) | MAPTSMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL15960257 | 0.87 | RARB (0.63) | MAPTSMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL28933332 | 0.87 | HPGD (0.50) | MAPTSMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL24808421 | 0.84 | VCP (0.74) | MAPTSMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL7739110 | 0.84 | ASIC3 (0.62) | MAPTSMN1; SMN2HPGDALDH1A1GRM5 | |
| SCHEMBL10411946 | 0.82 | ACACB (0.49) | MAPTSMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL3753633 | 0.82 | CES2 (0.64) | MAPTGRM5APPFFAR1VCP | |
| SCHEMBL402518 | 0.82 | RARB (0.62) | GRM5APPFFAR1MMP2MMP9 | |
| SCHEMBL12182347 | 0.82 | ACACB (0.57) | MAPTSMN1; SMN2HPGDALDH1A1APP | |
| SCHEMBL28950553 | 0.81 | MAPT (0.47) | MAPTSMN1; SMN2HPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554797-A1 | ANTI-COUNTERFEITING LABEL FOR THE AUTHENTICATION OF GOODS | Politecnico di Milano (IT) | 2025-05-21 | — | — | EP | claimed |
| WO-2024013693-A1 | ANTI-COUNTERFEITING LABEL FOR THE AUTHENTICATION OF GOODS | POLITECNICO DI MILANO (IT) | 2024-01-18 | — | — | WO | claimed |
| EP-0744391-B1 | Process for the preparation of aromatic acetyles using palladacyclen as acatalysts | AVENTIS RES & TECH GMBH & CO (DE) | 2001-09-26 | — | — | EP | claimed |
| EP-4570317-A2 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | Intervet International B.V. (NL) | 2025-06-18 | — | — | EP | disclosed |
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | INTERVET INC. (US) | 2025-02-18 | — | — | US | disclosed |
| CN-113825735-B | Carbon-carbon bond formation method | 奥加诺株式会社 | 2025-01-07 | — | — | CN | disclosed |
| US-12157717-B2 | Compounds for the treatment of bovine or swine respiratory disease | INTERVET INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-12077488-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | INTERVET INC. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-117466695-A | Cobalt-catalyzed alkyne synthesis method | 合肥工业大学 | 2024-01-30 | — | — | CN | disclosed |
| US-20230232826-A1 | USE OF 4-(PHENYLETHYNYL) BENZOIC ACID | CHINA JILIANG UNIVERSITY (CN) | 2023-07-27 | — | — | US | disclosed |
| CN-110072844-B | Compounds for the treatment of infection by Mannheimia haemolytica or histophilus somni | 英特维特国际股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-0729465-B1 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE DAVIS & CO (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6005103-A | TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AND DISEASES, INCLUDING AIDS | WARNER-LAMBERT COMPANY (US) | 1999-12-21 | — | — | US | disclosed |
| US-5886240-A | Process for preparing aromatic acetylenes using palladacycles as catalysts | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-03-23 | — | — | US | disclosed |
| US-5808062-A | AIDS THERAPY | WARNER-LAMBERT COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| US-5723573-A | ACETYLENIC END GROUPS | HITACHI CHEMICAL COMPANY, LTD. (JP) | 1998-03-03 | — | — | US | disclosed |
| EP-0729466-A1 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995014014-A2 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |
| US-5185363-A | Administering for treatment of inflammatory diseases | ABBOTT LABORATORIES (US) | 1993-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077488-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | SORD, HEXD, SNRPD1 | MAPT 3738/4885SMN1; SMN2 2241/4885HPGD 28/4885 |
| US-20230232826-A1 | USE OF 4-(PHENYLETHYNYL) BENZOIC ACID | BOLA2; BOLA2B, BCL2L10, EIF4G1 | MAPT 4638/4885SMN1; SMN2 4816/4885HPGD 4196/4885 |
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | SORD, HEXD, SNRPD1 | MAPT 4017/4885SMN1; SMN2 2033/4885HPGD 37/4885 |
| US-12157717-B2 | Compounds for the treatment of bovine or swine respiratory disease | PIGS, BTD, PPARD | MAPT 2194/4885SMN1; SMN2 2513/4885HPGD 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.